Home › Funds › BlackRock › BlackRock Health Sciences Opportunities Portfolio
Fund family: BlackRock · Filed by BLACKROCK FUNDS (CIK 844779) · SEC series S000001877
Share classes and tickers: SHISX (C000004913), SHSAX (C000004914), SHSCX (C000004916), SHSSX (C000004912)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,146 with, 25 against, 18 abstentions (not counted as with management); 5 items carried no recommendation. Shareholder proposals: 0 FOR, 25 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as BlackRock’s manager page (1,606,521 ballot items across 392 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | BlackRock | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 96.4% | 1,101 | 93.6% | 1,355,861 |
| Backed environmental and social shareholder proposals at US companies | n/a | 5 | 5.5% | 6,306 |
Each ballot item this fund voted is set against the votes of the other BlackRock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most BlackRock funds on 36 items (3.2% of the 1,109 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most BlackRock funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| GE HEALTHCARE TECHNOLOGIES INC. | 2026-05-07 | Election of Directors Catherine Lesjak | Against | FOR — 35 of 38 BlackRock funds | Against | — |
| ROIVANT SCIENCES LTD. | 2025-09-10 | To cast a non-binding, advisory vote to approve the compensation of our named executive officers. | For | AGAINST — 32 of 35 BlackRock funds | For | Approved, 60.9% support |
| THE COOPER COMPANIES, INC. | 2026-04-07 | Approve, on a non-binding, advisory basis, the compensation of our Named Executive Officers. | Against | FOR — 48 of 56 BlackRock funds | Against | Approved, 89.9% support |
| HUMANA INC. | 2026-04-16 | Election of Directors Wayne A. I. Frederick, M.D. | For | AGAINST — 41 of 48 BlackRock funds | For | — |
| BIO-TECHNE CORP | 2025-10-30 | Approve, on an advisory basis, the compensation of our executive officers. | Against | FOR — 35 of 42 BlackRock funds | Against | Approved, 72.1% support |
| HOLOGIC, INC. | 2026-02-05 | A proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the transactions contemplated by the merger agreement, including consummation of the merger. | For | AGAINST — 50 of 64 BlackRock funds | For | — |
| DENALI THERAPEUTICS INC. | 2026-06-03 | DIRECTOR: Jennifer Cook | For | ABSTAIN — 15 of 17 BlackRock funds | For | — |
| INCYTE CORPORATION | 2026-06-08 | Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. | For | AGAINST — 54 of 73 BlackRock funds | For | Approved, 83.9% support |
| EXACT SCIENCES CORPORATION | 2026-02-20 | Proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to Exact Sciences Corporation's named executive officers that is based on or otherwise related to the Merger Agreement and the transactions contemplated by the Merger Agreement (the "Compensat | For | AGAINST — 31 of 40 BlackRock funds | For | — |
| INCYTE CORPORATION | 2026-06-08 | Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jean-Jacques Bienaimé | For | AGAINST — 44 of 60 BlackRock funds | For | — |
| KODIAK SCIENCES INC. | 2026-06-02 | Elect three Class II directors nominated by our board and named in this proxy statement. Charles A. Bancroft | Withhold | FOR — 12 of 14 BlackRock funds | Against | — |
| WAVE LIFE SCIENCES LTD. | 2025-08-05 | To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd. | Against | FOR — 14 of 17 BlackRock funds | Against | Approved, 78.2% support |
| RADNET, INC. | 2026-06-02 | DIRECTOR: Laura P. Jacobs | Abstain | FOR — 17 of 22 BlackRock funds | Against | — |
| GALDERMA GROUP AG | 2026-04-22 | Approve Remuneration Report (Non-Binding) | Against | FOR — 31 of 43 BlackRock funds | Against | — |
| SUMMIT THERAPEUTICS INC. | 2026-06-10 | Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to Increase the Number of Shares of Common Stock. | For | AGAINST — 14 of 18 BlackRock funds | For | Passed (calculated), 95.8% support |
| SUMMIT THERAPEUTICS INC. | 2026-06-10 | DIRECTOR: Kenneth A. Clark | For | ABSTAIN — 14 of 18 BlackRock funds | For | — |
| APOGEE THERAPEUTICS, INC. | 2026-06-09 | DIRECTOR: William (BJ) Jones, Jr. | For | ABSTAIN — 12 of 15 BlackRock funds | For | — |
| SCHOLAR ROCK HOLDING CORPORATION | 2026-06-04 | DIRECTOR: Kristina Burow | For | ABSTAIN — 14 of 19 BlackRock funds | For | — |
| DYNE THERAPEUTICS, INC. | 2026-06-05 | To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. Jason Rhodes | Withhold | FOR — 14 of 19 BlackRock funds | Against | — |
| AVIDITY BIOSCIENCES, INC. | 2026-02-26 | To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement. | For | AGAINST — 23 of 34 BlackRock funds | For | Approved, 82.4% support |
| VIKING THERAPEUTICS INC | 2026-05-19 | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. | For | AGAINST — 25 of 38 BlackRock funds | For | Approved, 70.2% support |
| PROTAGONIST THERAPEUTICS, INC. | 2026-06-17 | DIRECTOR: L.T. Williams, MD, PhD | Abstain | FOR — 19 of 28 BlackRock funds | Against | — |
| NOVOCURE LIMITED | 2026-06-03 | The approval of our amended and restated 2024 Omnibus Incentive Plan. | Against | FOR — 13 of 18 BlackRock funds | Against | Approved, 50.3% support |
| BRIGHT MINDS BIOSCIENCES INC. | 2026-03-31 | DIRECTOR: David Weiner | Abstain | FOR — 8 of 10 BlackRock funds | Against | — |
| BRIGHT MINDS BIOSCIENCES INC. | 2026-03-31 | DIRECTOR: Jan Pedersen | Abstain | FOR — 8 of 10 BlackRock funds | Against | — |
| Company | Meeting | Item | This fund | Most BlackRock funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| BRIGHT MINDS BIOSCIENCES INC. | 2026-03-31 | DIRECTOR: Jeremy Fryzuk | Abstain | FOR — 8 of 10 BlackRock funds | Against | — |
| THERMO FISHER SCIENTIFIC INC. | 2026-05-20 | An advisory vote to approve named executive officer compensation. | Against | FOR — 40 of 67 BlackRock funds | Against | Not approved, 31.8% support |
| GALDERMA GROUP AG | 2026-04-22 | Approve Remuneration of Executive Committee in the Amount of CHF 31.2 Million | Against | FOR — 21 of 32 BlackRock funds | Against | — |
| ZEALAND PHARMA A/S | 2026-03-26 | REELECT ALF GUNNAR MARTIN NICKLASSON AS DIRECTOR | For | ABSTAIN — 11 of 15 BlackRock funds | For | — |
| VIKING THERAPEUTICS INC | 2026-05-19 | DIRECTOR: J. Matthew Singleton | For | ABSTAIN — 18 of 28 BlackRock funds | For | — |
| GALDERMA GROUP AG | 2026-04-22 | Transact Other Business (Voting) | Abstain | FOR — 20 of 32 BlackRock funds | Against | — |
| MODERNA, INC. | 2026-05-06 | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Against | FOR — 33 of 59 BlackRock funds | Against | Approved, 65.1% support |
| MERUS N.V. | 2025-12-09 | Non-binding advisory proposal to approve certain compensation arrangements | For | AGAINST — 12 of 19 BlackRock funds | For | Passed (calculated), 55.9% support |
| ZEALAND PHARMA A/S | 2026-03-26 | AUTHORIZE SHARE REPURCHASE PROGRAM | For | ABSTAIN — 8 of 12 BlackRock funds | For | — |
| ZEALAND PHARMA A/S | 2026-03-26 | ELECT IRIS LOEW FRIEDRICH AS NEW DIRECTOR | For | ABSTAIN — 8 of 12 BlackRock funds | For | — |
| ZEALAND PHARMA A/S | 2026-03-26 | REELECT ELAINE SULLIVAN AS DIRECTOR | For | ABSTAIN — 8 of 12 BlackRock funds | For | — |
Download all 36 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 82.3% of this fund’s 1,189 such votes could be given a sector; the other 211 (17.7%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 885 | 24 | 2.7% |
| Industrials | 76 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 756 | 0 |
| Say-on-Pay | 132 | 0 |
| Audit-related | 129 | 0 |
| Corporate Governance | 63 | 14 |
| Compensation | 54 | 1 |
| Capital Structure | 33 | 0 |
| Shareholder Rights and Defenses | 19 | 5 |
| Extraordinary Transactions | 10 | 0 |
| Other Social Issues | 9 | 4 |
| Human Rights or Human Capital/workforce | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| ELI LILLY AND COMPANY | May 4, 2026 | $1.0B | 10 | 2 |
| JOHNSON & JOHNSON | April 23, 2026 | $760M | 15 | 1 |
| MERCK & CO., INC. | May 26, 2026 | $385M | 18 | 3 |
| ABBVIE INC. | May 8, 2026 | $341M | 8 | 1 |
| GILEAD SCIENCES, INC. | April 30, 2026 | $291M | 15 | 3 |
| UNITEDHEALTH GROUP INCORPORATED | June 1, 2026 | $279M | 12 | 1 |
| AMGEN INC. | May 19, 2026 | $272M | 15 | 1 |
| EDWARDS LIFESCIENCES CORPORATION | May 7, 2026 | $183M | 12 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | JOHNSON & JOHNSON | Independent Board Chair Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 8, 2026 | ABBVIE INC. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| June 1, 2026 | UNITEDHEALTH GROUP INCORPORATED | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 19, 2026 | AMGEN INC. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| May 13, 2026 | VERTEX PHARMACEUTICALS INCORPORATED | Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 5, 2026 | BRISTOL-MYERS SQUIBB COMPANY | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | Against | For |
1,206 ballot items at 138 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, BlackRock Health Sciences Opportunities Portfolio (SHISX) voted at 138 shareholder meetings of 131 companies, on 1,206 ballot items in all. Where management made a recommendation, the fund followed it on 96.4% of the items and voted against it 25 times. Its most frequent area of disagreement was corporate governance (14 of its votes against management). It voted on 25 shareholder proposals. It voted FOR the board's own proposals more often than BlackRock's funds as a whole (96.4% against 93.6%). It voted differently from most BlackRock funds on 36 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BlackRock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.